OREXO US INC
MORRISTOWN, NEW JERSEY 079603965
$16.90M
Total Contract Value
10 awards
First Award
Nov 8, 2022
Last Award
Sep 24, 2025
Business Size
small
CAGE Code
6Y7L3
Top Industries (NAICS)
| NAICS Code | Obligations | Awards |
|---|---|---|
| 541714 | $8.45M | 1 |
| 325412 | $0 | 7 |
| 334510 | $0 | 1 |
Contract Awards
1 awards found
75A50125C00010
Department of Health and Human Services
$8.45M
Sep 24, 2025
CLINICAL DEVELOPMENT OF OX390 (ATIPAMEZOLE) AS AN ?2 AGONIST REVERSAL AGENT FOR HUMAN USE TO COUNTERACT THE SEDATIVE EFFECTS OF XYLAZINE, MEDETOMIDINE, AND OTHER ?2 AGONISTS
NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2025
Business Details
- UEI
- MN1MPMBCVVD5
- CAGE Code
- 6Y7L3
- Address
- 150 HEADQUARTERS PLZ EAST TOWER
MORRISTOWN, NJ 079603965 - Congressional District
- NJ-11
- Phone
- 9739366906
Parent Company
OREXO AB
Data Source
This profile is based on federal contract award data from USAspending.gov.
View on USAspending.gov